natgillin/translations-raw huggingface dataset:
In cattle, Inflacam is used together with appropriate antibiotic therapy, to reduce clinical signs of disease in acute respiratory infection (infection of the lungs and airways).
Pri govedu se zdravilo Inflacam uporablja skupaj z ustreznim antibiotičnim zdravljenjem za zmanjšanje kliničnih znakov akutne okužbe dihal (okužbe pljuč in dihalnih poti).
In cattle, it is postulated that metabolism of tildipirosin proceeds by cleavage of the mycaminose sugar moiety, by reduction and sulphate conjugation with subsequent hydration (or ring opening), by demethylation, by mono- or dihydroxylation with subsequent dehydration and by S-cysteine and S- glutathione conjugation.
Pri govedu se predpostavlja, da metabolizem tildipirozina poteka z odcepitvijo micaminose dela sladkorja, z zmanjševanjem in konjugacijo sulfata z naknadno hidraciji (ali odprtjem obroča), z demetilacijo, z mono- ali dihidroksilacijo s posledično dehidracijo in s konjugacijo S-cisteina in S- glutationa.
In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound.
Pri govedu je tudi pomembna sestavina pri izločanju zdravila z mlekom in žolčem, medtem ko urin vsebuje samo sledi matične spojine.
In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound.
Pri govedu se večina meloksikama izloči z mlekom in žolčem, medtem ko vsebuje urin samo sledi osnovne učinkovine.
In cattle, meloxicam is also a major excretion product in milk.
Meloksikam se presnavlja v alkohol, kisli derivat in več polarnih presnovkov.
In cattle, Metacam is used together with appropriate antibiotic therapy, to reduce clinical signs of disease, in acute (short-term) respiratory infection (infection of the lungs and airways).
Pri govedu se zdravilo Metacam uporablja skupaj z ustreznim antibiotičnim zdravljenjem za zmanjšanje kliničnih znakov akutne okužbe dihal (okužbe pljuč in dihalnih poti).
In cattle, pigs and horses in very rare cases anaphylactoid reactions (allergic) which may be serious (including fatal) may occur and should be treated symptomatically.
Pri govedu, prašičih in konjih se lahko v zelo redkih primerih pojavijo anafilaktične (alergijske) reakcije, ki utegnejo biti resne (tudi smrtne) in jih je treba zdraviti simptomatsko.
In cattle, Rheumocam is used together with appropriate antibiotic therapy, to reduce clinical signs of disease, in acute respiratory infection (infection of the lungs and airways).
Pri govedu se zdravilo Rheumocam uporablja skupaj z ustreznimi antibiotiki za zmanjšanje kliničnih znakov bolezni pri akutni okužbi dihal (okužbi pljuč in dihalnih poti).
In cattle, safety during pregnancy was extrapolated from a study that was conducted in pregnant cows with a similar vaccine to Bluevac BTV8 which contained a different serotype (serotype 1).
Pri govedu je bila varnost med brejostjo ekstrapolirana iz študije, ki je bila izvedena pri brejih kravah s podobnim cepivom, kot je cepivo Bluevac BTV8, ki je vsebovalo drug serotip (serotip 1).
In cattle, the antibody levels measured were above those shown to be protective.
Pri govedu so izmerjene vrednosti protiteles nad tistimi, ki dokazano zaščitijo živali.
In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira 80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well among the adalimumab treatment groups compared to the placebo group.
Študiji pri Crohnovi bolezni I in II sta pokazali statistično značilno izboljšanje celotnega seštevka po vprašalniku IBDQ (vprašalnik, specifičen za vnetno bolezen črevesa) do 4. tedna pri bolnikih, randomiziranih na shemi z zdravilom Humira 80/40 mg in 160/80 mg, v primerjavi s placebom; razliko 26. in 56. teden je v skupinah, zdravljenih z adalimumabom, v primerjavi s placebom pokazala tudi študija pri Crohnovi bolezni III.
In CD Study I, 299 TNF-antagonist naive patients were randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and 80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2.
V obdobju A so bolniki prejemali placebo ali zdravilo Humira v začetnem odmerku 160 mg v 0. tednu, nato 80 mg v 2. tednu in 40 mg vsak teden od vključno 4. tedna do 11. tedna.
In CD Study I, 299 TNF-antagonist naive patients were randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and 80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2.
V študiji Crohnove bolezni I je bilo 299 bolnikov, ki še niso prejemali TNF-antagonistov, randomiziranih v eno od štirih skupin; placebo v 0. in 2. tednu, 160 mg zdravila Humira v 0. tednu in 80 mg v 2. tednu, 80 mg v 0. tednu in 40 mg v 2. tednu in 40 mg v 0. tednu in 20 mg v 2. tednu.
In CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at weeks 0 and 2.
V obdobju A so bolniki prejeli placebo ali zdravilo Humira v začetnem odmerku 160 mg v 0. tednu, nato 80 mg v
In CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2.
V študiji Crohnove bolezni II je bilo 325 bolnikov, ki so postali neodzivni ali so imeli intoleranco na infliksimab, randomiziranih, da so prejeli ali 160 mg zdravila Humira v 0. tednu in 80 mg v 2.tednu ali placebo v 0. in 2. tednu.
In CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at weeks 0 and 2.
V študiji pri Crohnovi bolezni II so 325 bolnikov, ki so se nehali odzivati na infliksimab ali ga niso prenesli, randomizirali bodisi na 160 mg zdravila Humira 0. teden in 80 mg 2. teden bodisi na placebo 0. in 2. teden.
In CD Study III, 854 patients received open-label 80 mg at Week 0 and 40 mg at Week 2.
2. tednu in 40 mg vsak teden od vključno 4. tedna do 11. tedna.
In CD Study III, 854 patients received open-label 80 mg at Week 0 and 40 mg at Week 2.
V tej študiji je 854 bolnikov odprto prejelo 80 mg v 0. tednu in 40 mg v 2. tednu.
In CD Study III, 854 patients received open-label 80 mg at Week 0 and 40 mg at Week 2.
V študiji pri Crohnovi bolezni III je 854 bolnikov po odprtem protokolu dobilo 80 mg 0. teden in 40 mg 2. teden.
In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the primary analysis.
V študiji pri Crohnovi bolezni III je imelo 4. teden klinični odziv 58 % (499/854) bolnikov; ti so bili ocenjeni v primarni analizi.
In cell culture Emtricitabine
V celični kulturi Emtricitabin
In cell culture Genotype 1
V celični kulturi Genotip 1
In cellular anti-proliferation assays the inhibitory concentration 50 (IC50) against V600 mutated cell lines (V600E, V600R, V600D and V600K mutated cell lines) ranged from 0.016 to 1.131 M whereas the IC50 against BRAF wild type cell lines were 12.06 and 14.32 M, respectively.
Pri testih proliferacije celic je bila inhibitorna koncentracija 50 (IC50) pri V600 mutiranih celičnih linijah (V600E, V600R, V600D in V600K mutiranih celičnih linijah) med 0,016 in 1,131 µM, medtem ko je bila IC50 pri BRAF divjem tipu celičnih linij med 12,06 in 14,32 µM.
In certain cases treatment should be
V določenih primerih je treba zdravljenje trajno ukiniti.
In certain cases treatment should be permanently stopped.
V določenih primerih je
In certain clinical situations, a dosage of 15–30 ml/kg may be appropriate.
Pri nekaterih kliničnih stanjih je primeren odmerek 15-30 ml/kg.
In certain individual cats Notoedres cati infestation may be severe or complicated by bacterial infections.
Pri posameznih mačkah je lahko okužba z Notoedres cati zelo močna ali se komplicira s sekundarno bakterijsko okužbo.
In certain individual cats Notoedres cati infestation may be severe.
V posameznih primerih se lahko pojavijo hude okužbe mačk s pršicami vrste Notoedres cati.
In certain people taking levothyroxine (a thyroid hormone) and Renagel, increased levels of thyroid stimulating hormone (TSH, a substance in your blood which helps control your body’s chemical functions) may very rarely be observed.
Pri nekaterih ljudeh, ki jemljejo levotiroksin (tiroidni hormon) in zdravilo Renagel, so zelo redko opazili zvišane ravni tiroideo stimulirajočega hormona (TSH, snov v krvi, ki pomaga nadzirati kemijske funkcije telesa).
In certain people taking levothyroxine (a thyroid hormone) and Renagel, increased levels of thyroid stimulating hormone (TSH, a substance in your blood which helps control your body’s chemical functions) may very rarely be observed.
Pri nekaterih ljudeh, ki jemljejo levotiroksin (tiroidni hormon) in zdravilo Renagel, so zelo redko opazili žvišane ravni tiroideo stimulirajočega hormona (TSH, snov v krvi, ki pomaga nadzirati kemijske funkcije telesa).
In certain people taking levothyroxine (a thyroid hormone) and Tasermity, increased levels of thyroid stimulating hormone (TSH, a substance in your blood which helps control your body’s chemical functions) may very rarely be observed.
Pri nekaterih ljudeh, ki jemljejo levotiroksin (tiroidni hormon) in zdravilo Tasermity, so zelo redko opazili zvišane ravni tiroideo stimulirajočega hormona (TSH, snov v krvi, ki pomaga nadzirati kemijske funkcije telesa).
In certain situations the doctor may decide to adjust the dose required to prevent bleeding, based on the patient’s factor XIII levels in the blood.
V določenih primerih se lahko zdravnik na podlagi analize bolnikove ravni faktorja XIII v krvi odloči, da prilagodi odmerek, potreben za preprečevanje krvavitev.
In certain situations, for example if you are 75 years or older, your doctor may recommend a starting dose of mg once a week.
Če ste starejši od 75 let vam lahko vaš zdravnik priporoči začetni odmerek 0,75 mg enkrat na teden.
In chemotherapy naïve patients treated for non-small cell lung cancer, the recommended dose regimen is docetaxel 75 mg/m2 immediately followed by cisplatin 75 mg/m2 over 30-60 minutes.
Pri bolnikih z nedrobnoceličnim pljučnim rakom, ki se še niso zdravili s kemoterapijo, je priporočeni režim odmerjanja docetaksel v odmerku 75 mg/m2, ki mu takoj sledi 30- do 60-minutna aplikacija cisplatina v odmerku 75 mg/m2.
In chemotherapy naïve patients treated for non-small cell lung cancer, the recommended dose regimen is docetaxel 75 mg/m2 immediately followed by cisplatin 75 mg/m2 over 30-60 minutes.
Pri bolnikih z nedrobnoceličnim pljučnim rakom, ki še niso bili zdravljeni s kemoterapijo, je priporočena shema odmerjanja docetaksel v odmerku 75 mg/m2, ki mu takoj sledi cisplatin v odmerku 75 mg/m2, apliciran 30–60 minut.
In chickens and turkeys: Dicural oral solution is indicated for treatment of chronic respiratory infections caused by sensitive strains of Escherichia coli and Mycoplasma gallisepticum.
Zdravljenje kroničnih respiratornih infekcij pri piščancih in puranih, ki jih povzročajo na difloksacin občutljivi mikroorganizmi: Escherichia coli in Mycoplasma gallisepticum.
In chickens:
Pri piščancih:
In children (6 years of age or older) treated for Crohn’s disease or ulcerative colitis, the recommended dose is the same as for adults.
Pri otrocih (starih 6 let ali več), ki se zdravijo zaradi Chronove bolezni ali ulceroznega kolitisa, je priporočeni odmerek enak kot pri odraslih.
In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg/day.
Pri otrocih (starih od 2 do 11 let), ki so dobivali kaspofungin v odmerku 50 mg/m2 na dan (največ 70 mg na dan), je bila AUC0-24h kaspofungina v plazmi po večkratnih odmerkih primerljiva kot pri odraslih, ki so dobivali 50 mg kaspofungina na dan.
In children 12 to 23 months of age, the vaccine may also be administered in the anterolateral part of the thigh (see sections 4.4 and 4.5).
Otroci, stari od 12 do 23 mesecev, lahko cepivo dobijo tudi v anterolateralni del stegna (glejte poglavji 4.4 in 4.5).
In children aged 1 to 17 years, the recommended dose is 10 mg three times a day in children weighing less than 20 kg and 20 mg three times a day in those over 20 kg.
Pri otrocih v starosti od enega do 17 let je priporočeni odmerek 10 mg trikrat na dan pri otrocih, ki tehtajo manj kot 20 kg ter 20 mg trikrat na dan pri tistih, ki tehtajo več kot 20 kg.
In children aged 12-23 months, the immune responses elicited after two doses were comparable to the responses elicited after three doses in infants below 6 months of age, except for vaccine serotypes 18C and 19F as well as serotype 19A for which responses were higher in the 12-23 months children.
Pri otrocih, starih od 12 do 23 mesecev, je bil imunski odziv dosežen z dvema odmerkoma, primerljiv odzivu doseženem po treh odmerkih pri dojenčkih, mlajših od 6 mesecev, razen za serotipa v cepivu 18C in 19F in serotip 19A, za katere so bili odzivi večji pri otrocih v starosti od 12 do 23 mesecev.
In children aged 2 months to <3 years, the following side effects have been observed more frequently compared to children aged 3 years to <12 years, adolescents and adults:
Pri otrocih, starih 2 meseca do < 3 leta, so pogosteje opazili naslednje neželene učinke v primerjavi z otroci, starimi 3 leta do < 12 let, mladostniki in odraslimi:
In children aged 2 to 5 years that received 1 dose, the ELISA antibody GMCs were similar for 6 vaccine serotypes as well as serotype 19A than those achieved following a 3-dose vaccination schedule in infants below 6 months of age while they were lower for 4 vaccine serotypes (serotypes 1, 5, 14 and 23F).
Pri otrocih, starih od 2 do 5 let, ki so dobili 1 odmerek, so bile GMC protiteles z ELISA podobne za 6 serotipov v cepivu in za serotip 19A v primerjavi s tistimi doseženimi po shemi cepljenja s 3 odmerki pri dojenčkih mlajših od 6 mesecev, medtem ko so bile za 4 serotipe v cepivu nižje (serotipi 1, 5, 14 in 23F).
In children aged 2 to 5 years the most common side effects are nasal congestion (26.5 %), upper respiratory tract infection (23.5 %), increase in liver enzymes (14.7 %), rash (11.8 %) and bacteria in sputum (11.8 %).
Pri otrocih, starih od dve do pet let, so najpogostejši neželeni učinki zamašen nos (26,5 %), okužbe zgornjih dihal (23,5 %), povečanje jetrnih encimov (14,7 %), izpuščaj (11,8 %) in bakterije v izpljunku (11,8 %).
In children aged 6 to less than 12 years, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 x ULN was 15.0% (6/40) in ivacaftor-treated patients and 14.6% (6/41) in patients who received placebo.
Pri otrocih, starih od 6 do manj kot 12 let, je bila pogostost bolnikov z zvišanjem transaminaz (ALT ali AST) > 3 x ULN 15,0 % (6/40) pri tistih, zdravljenih z ivakaftorjem, in 14,6 % (6/41) pri bolnikih, ki so prejemali placebo.
In children aged 6-35 months who received two doses of 0.25 ml of Pandemrix (H1N1), there was an increase in reports of pain, redness and swelling at the injection site as well as fever (>38°C), drowsiness, irritability and loss of appetite after the second dose compared to the first dose.
Pri otrocih, starih od 6 do 35 mesecev, ki so dobili dva 0,25 ml ml odmerka cepiva Pandemrix (H1N1)v, so več poročali o bolečini, rdečini in oteklosti na mestu injiciranja ter o zvišani telesni temperaturi (> 38 °C), zaspanosti, razdražljivosti in izgubi apetita po drugem odmerku v primerjavi s prvim odmerkom.
In children aged between two months and three years, half the adult dose of Ixiaro (0.25 ml) should be given, and an additional 0.25 ml dose should be given four weeks later.
Pri otrocih, starih od dveh mesecev do treh let, je treba uporabiti polovični odmerek cepiva Ixiaro (0,25 ml), ki mu sledi še en 0,25-mililitrski odmerek štiri tedne kasneje.
In children aged from 2 months to 9 months plasma concentrations of retapamulin were measurable in 69% (20/29) of samples.
Pri otrocih v starosti od 2 do 9 mesecev je bila koncentracija retapamulina v plazmi merljiva v 69 % vzorcev (20/29).
In children aged less than 3 years, fever, diarrhoea, influenza-like illness, irritability and redness at injection site were the most common side effects (seen in more than 1 of 10 children) and in children aged 3 years and older, fever and injection site pain and tenderness were most common.
Pri otrocih, mlajših od treh let, so bili najpogostejši neželeni učinki (opaženi pri več kot 1 otroku od 10) povišana telesna temperatura, driska, gripi podobni simptomi ter razdražljivost in pordelost na mestu injiciranja, medtem ko sta bila pri otrocih, starejših od treh let, najpogostejša neželena učinka povišana telesna temperatura ter bolečina in občutljivost na mestu injiciranja.
In children aged three to 11 years, the ‘test meal’ should be 100 ml of pure orange juice.
Pri otrocih, starih od treh do 11 let, je „testni obrok“ 100 ml čistega pomarančnega soka.
In children ages 6 – 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common) and abnormal liver enzymes (uncommon).
Pri otrocih, starih 6–17 let, so neželeni učinki skladni s tistimi, opisanimi spodaj, z naslednjimi izjemami: pljučnica, dehidracija, zmanjšanje potenja (pogosti) in nenormalni rezultati jetrnih encimov (občasni).
In children ages 6 – 17 years old, side effects were consistent with those described below with the following exceptions: pneumonia, dehydration, sweating decreased (common), abnormal liver enzymes (uncommon), middle ear infection, sore throat, sinus and chest infections, cough, nosebleeds, runny nose, stomach pain, vomiting, rash, eczema and fever.
Pri otrocih, starih 6–17 let, so neželeni učinki skladni s tistimi, opisanimi spodaj, z naslednjimi izjemami: pljučnico, dehidracijo, zmanjšanjem potenja (pogosti), nenormalnimi rezultati jetrnih encimov (občasni), okužbami srednjega ušesa, vnetim grlom, okužbami sinusov in prsnega koša, kašljem, krvavitvami iz nosu, izcedkom iz nosu, bolečino v trebuhu, bruhanjem, izpuščajem, ekcemom in vročino.
In children and adolescent patients 1st dose reduction of ribavirin is to 12 mg/kg/day, 2nd dose reduction of ribavirin is to 8 mg/kg/day.
Pri otrocih in mladostnikih je prvo zmanjšanje odmerka ribavirina na 12 mg/kg/dan, drugo zmanjšanje odmerka ribavirina pa na 8 mg/kg/dan.
In children and adolescent patients receiving body surface area-adjusted dosing of ViraferonPeg at 60 µg/m2/week, the log transformed ratio estimate of exposure during the dosing interval is predicted to be 58 % (90 % CI: 141-177 %) higher than observed in adults receiving 1.5 µg/kg/week.
Pri otrocih in mladostnikih, ki so prejemali na telesno površino prilagojen odmerek zdravila ViraferonPeg 60 µg/m2 na teden, je bila napovedana logaritemska vrednost ocene izpostavljenosti zdravilu v času odmernega intervala za 58 % (90 % IZ: 141-177 %) večja od ugotovljene vrednosti pri odraslih, ki so prejemali odmerek 1,5 µg/kg na teden.
In children and adolescent patients receiving body surface area-adjusted dosing of ViraferonPeg at 60 g/m2/week, the log transformed ratio estimate of exposure during the dosing interval is predicted to be 58 % (90 % CI: 141-177 %) higher than observed in adults receiving 1.5 g/kg/week.
Pri otrocih in mladostnikih, ki so prejemali na telesno površino prilagojen odmerek zdravila ViraferonPeg 60 µg/m2 na teden, je bila napovedana logaritemska vrednost ocene izpostavljenosti zdravilu v času odmernega intervala za 58 % (90 % IZ: 141-177 %) večja od ugotovljene vrednosti pri odraslih, ki so prejemali odmerek 1,5 µg/kg na teden.
In children and adolescent patients treated with Ribavirin BioPartners plus interferon alfa-2b, reduce ribavirin dose to 7.5 mg/kg/day.
Pri otrocih in mladostnikih, zdravljenih z zdravilom Ribavirin BioPartners in interferonom alfa-2b, pa odmerek zdravila Ribavirin BioPartners zmanjšajte na 7,5 mg/kg na dan.
In children and adolescent patients treated with Ribavirin Teva Pharma B.V. plus interferon alfa-2b, reduce ribavirin dose to 7.5 mg/kg/day.
Pri otrocih in mladostnikih, zdravljenih z zdravilom Ribavirin Teva Pharma B.V. in interferonom alfa-2b, pa odmerek zdravila Ribavirin Teva Pharma B.V. zmanjšajte na 7,5 mg/kg na dan.
In children and adolescent PNH patients (aged 11 years to less than 18 years) included in the paediatric PNH Study M07-005, the safety profile appeared similar to that observed in adult PNH patients.
Pri otrocih in mladostnikih s PNH (starih od 11 do manj kot 18 let), ki so bili vključeni v pediatrično študijo PNH M07-005, se je zdel varnostni profil podoben kot so ga opazovali pri odraslih bolnikih s PNH.
In children and adolescents however it may be used to treat all stages of the illness.
Pri otrokih in mladostnikih se lahko zdravilo Imatinib Accord uporablja tudi za zdravljenje vseh stadijev bolezni.
In children and adolescents its use is only for those who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Njegova uporaba pri otrocih in mladostnikih je namenjena le tistim, ki jih ni mogoče zdraviti z drugimi nukleotidnimi zaviralci reverzne transkriptaze (NRTI) prve izbire.
In children and adolescents pain was the most frequently reported solicited local reaction, and fatigue and headache were the most commonly reported solicited systemic reactions.
Pri otrocih in mladostnikih je bila bolečina najpogostejša izzvana lokalna reakcija, utrujenost in glavobol pa najpogostejši izzvani sistemski reakciji.
In children and adolescents with Sickle Cell Syndrome, systemic exposure to hydroxycarbamide is similar to adult patients.
Pri otrocih in mladostnikih s srpasto celičnim sindromom je sistemska izpostavljenost hidroksikarbamidu podobna kot pri odraslih bolnikih.
In children and adults with high blood pressure in the lungs, connected with heart surgery, INOmax is usually given for 24-48 hours.
Otrokom in odraslim, ki imajo visok krvni tlak v pljučih, povezan s kirurškim posegom na srcu, se zdravilo INOmax običajno daje 24–48 ur.
in children below 2 years of age, who may be at greater risk of side effects from any of the medicine absorbed through the skin. if you are taking certain medicines used for depression or Parkinson’s disease including so-called monoamine oxidase (MAO) inhibitors (for example selegiline or moclobemide) or tricyclic antidepressants (such as imipramine) or tetracyclic antidepressants (such as maprotiline, mianserin or mirtazapin).
pri otrocih, starih manj kot 2 leti, ki jih neželeni učinki katerega koli zdravila, ki se absorbira skozi kožo, lahko bolj ogrožajo. če uporabljate nekatera zdravila, ki se uporabljajo pri depresiji ali Parkinsonovi bolezni, vključno s tako imenovanimi zaviralci monoamin oksidaze (MAO) (npr. selegilin ali moklobemid), tricikličnimi antidepresivi (kot je imipramin) ali tetracikličnimi antidepresivi (kot so maprotilin, mianserin ali mirtazapin).
In children below the age of 12 years, higher doses or more frequent injections may be needed and the usual dose is 50 to 60 IU per kg of body weight, given once every 7 days.
Pri otrocih, starih do 12 let, bodo morda potrebni večji odmerki ali pogostejše injiciranje, običajni odmerek pa je od 50 do 60 i.e. na kg telesne mase, ki se daje enkrat vsakih 7 dni.
In children between 6 months and 12 years of age, Emend oral suspension is given together with a 5- HT3 antagonist.
Pri otrocih, starih od 6 mesecev do 12 let, se peroralna suspenzija zdravila Emend daje skupaj z antagonistom 5-HT3.
In children less than 10 years of age, the daily dose is 100 mg/kg/day given in 2 doses.
Pri otrocih, mlajših od 10 let, je dnevni odmerek 100 mg/kg/dan, razdeljen na 2 odmerka.
in children on haemodialysis
pri otrocih na hemodializi